Jennifer Lachey - 11 May 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
11 May 2021
Net transactions value
-$130,871
Form type
4
Filing time
13 May 2021, 16:36:12 UTC
Next filing
15 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $795 +2,650 +3.7% $0.3000* 73,837 11 May 2021 Direct
transaction KROS Common Stock Sale $132,500 -2,650 -3.6% $50.00 71,187 11 May 2021 Direct F1
transaction KROS Common Stock Options Exercise $684 +6,220 +8.7% $0.1100* 77,407 13 May 2021 Direct
transaction KROS Common Stock Options Exercise $150 +500 +0.65% $0.3000* 77,907 13 May 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -2,650 -2% $0.000000 132,355 11 May 2021 Common Stock 2,650 $0.3000 Direct F2
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -6,220 -100% $0.000000* 0 13 May 2021 Common Stock 6,220 $0.1100 Direct F2
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -500 -6% $0.000000 7,793 13 May 2021 Common Stock 500 $0.3000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.
F3 One-twelfth (1/12th) of the shares subject to the option vested or shall vest in equal quarterly installments commencing on March 18, 2018, subject to the Reporting Person continuing to provide service through each such date.